A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Study summary

This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in participants with metastatic non-small cell lung cancer (NSCLC). Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of participants with tumor PD-L1 expression who have received no prior systemic therapy for metastatic NSCLC, and Cohort 2 will consist of participants who experienced disease progression during or following treatment with a platinum-containing regimen and a PD-L1/PD-1 checkpoint inhibitor, given in combination as one line of therapy or as two separate lines of therapy, regardless of PD-L1 expression. In each cohort, eligible participants will initially be assigned to one of several treatment arms (Stage 1). Participants who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment regimen (Stage 2).

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedAtezolizumab and Cobimetinib

Plus 16 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · PD-L1 · Early-stage or resectable

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 12, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?29 U.S. locations

Locations may change over time.

Who runs it?Hoffmann-La Roche

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1 / Phase 2
Sponsor: Hoffmann-La Roche
Interventions being studied: Drug: Atezolizumab; Drug: Cobimetinib; Drug: RO6958688; Drug: Docetaxel; Drug: CPI-444; Drug: Pemetrexed; Drug: Carboplatin; Drug: Gemcitabine; Drug: Linagliptin; Drug: Tocilizumab; Drug: Ipatasertib; Drug: Bevacizumab; Drug: Sacituzumab Govitecan; Other: Radiation; Drug: Evolocumab; Drug: Tiragolumab; Drug: XL092; Drug: Camonsertib

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Disease setting

Early-stage or resectable→Metastatic or stage IV→

Biomarkers

PD-L1→

Treatment approach

Immunotherapy→Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

General
Eastern Cooperative Oncology Group (ECOG) performance Status of 0 or 1
Life expectancy greater than or equal to 3 months
Histologically or cytologically confirmed metastatic, non-squamous or squamous Non-Small Cell Lung Cancer (NSCLC)
Measurable disease (at least one target lesion)
Adequate hematologic and end-organ function
Tumor accessible for biopsy
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating eggs as outlined for each specific treatment arm
For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm Inclusion Criteria for Cohort 1
No prior systemic therapy for metastatic NSCLC
High tumor PD-L1 expression, defined as Tumor Proportion Score (TPS) or TCs \>= 50% or TC3 Inclusion Criteria for Cohort 2 \- Disease progression during or following treatment for metastatic or locally advanced, inoperable NSCLC

Reasons someone may not be able to joinExclusion criteria

Prior allogeneic stem cell or solid organ transplantation
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
History of leptomeningeal disease
Active or history of autoimmune disease or immune deficiency
History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan
History of malignancy other than NSCLC within 2 years prior to screening
Active tuberculosis
Severe infection within 4 weeks prior to initiation of study treatment

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Comprehensive Cancer Centers of Nevada (CCCN) - Central ValleyLas Vegas, Nevada
Columbia University Medical CenterNew York, New York
University Hospitals Case Medical CenterCleveland, Ohio
SCRI Oncology PartnersNashville, Tennessee
Blacktown HospitalBlacktown, New South Wales
Peter Mac Callum Cancer CenterEast Melbourne, Victoria
Centre Georges Francois LeclercDijon
Centre Léon BérardLyon
Hopital de la TimoneMarseille
Institut Régional du Cancer de MontpellierMontpellier
Institut De Cancerologie De L'OuestSaint-Herblain
Institut Universitaire du Cancer de Toulouse-OncopoleToulouse

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 12, 2026. Always confirm current availability with the study team.

View original record ↗